Operating Expenses
Acquired in-process research and development expenses
AbbVie Acquired in-process research and development expenses decreased by 41.2% to $744.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 200.0%, from $248.00M to $744.00M. Over 4 years (FY 2021 to FY 2025), Acquired in-process research and development expenses shows an upward trend with a 45.3% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
First reportedQ1 2013
Last reportedQ1 2026May 8, 2026
Metric ID:
pfe_acquired_iprd_expensesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $132.00M | $402.00M | $405.00M | $145.00M | $269.00M | $40.00M | $243.00M | $150.00M | $280.00M | $66.00M | $282.00M | $164.00M | $937.00M | $82.00M | $1.57B | $248.00M | $823.00M | $2.68B | $1.27B | $744.00M |
| QoQ Change | — | +204.5% | +0.7% | -64.2% | +85.5% | -85.1% | +507.5% | -38.3% | +86.7% | -76.4% | +327.3% | -41.8% | +471.3% | -91.2% | >999% | -84.2% | +231.9% | +225.6% | -52.8% | -41.2% |
| YoY Change | — | — | — | — | +103.8% | -90.0% | -40.0% | +3.4% | +4.1% | +65.0% | +16.0% | +9.3% | +234.6% | +24.2% | +458.2% | +51.2% | -12.2% | >999% | -19.6% | +200.0% |
Range$40.00M – $2.68B
CAGR+43.9%
Avg YoY Growth+261.0%
Median YoY Growth+20.1%
Current Streak2 quarters decline
Acquired in-process research and development expenses at Other Companies
Frequently Asked Questions
- What is AbbVie's acquired in-process research and development expenses?
- AbbVie (ABBV) reported acquired in-process research and development expenses of $744.00M in Q1 2026.
- How has AbbVie's acquired in-process research and development expenses changed year-over-year?
- AbbVie's acquired in-process research and development expenses increased by 200.0% year-over-year, from $248.00M to $744.00M.
- What is the long-term trend for AbbVie's acquired in-process research and development expenses?
- Over 4 years (2021 to 2025), AbbVie's acquired in-process research and development expenses has grown at a 45.3% compound annual growth rate (CAGR), from $1.12B to $5.02B.